دورية أكاديمية
أعرض في EDS

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies.

التفاصيل البيبلوغرافية
العنوان: Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies.
المؤلفون: Hong CT; Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Chan L; Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Chen KY; Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan., Lee HH; Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Huang LK; Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan., Yang YSH; Joint Biobank, Office of Human Research, Taipei Medical University, Taipei 11031, Taiwan., Liu YR; Joint Biobank, Office of Human Research, Taipei Medical University, Taipei 11031, Taiwan., Hu CJ; Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
المصدر: Cells [Cells] 2022 Nov 02; Vol. 11 (21). Date of Electronic Publication: 2022 Nov 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Gastrointestinal Microbiome*/physiology , Parkinson Disease*/drug therapy, Mice ; Animals ; Rifaximin/pharmacology ; Rifaximin/therapeutic use ; Inflammation/drug therapy ; Anti-Bacterial Agents/pharmacology
مستخلص: Patients with Parkinson's disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The study examined the effect of long-term rifaximin treatment on in vivo transgenic PD mice (MitoPark) and short-term rifaximin treatment on patients with PD. Rifaximin treatment caused a significant change in gut microbiota in the transgenic PD mice; in particular, it reduced the relative abundance of Prevotellaceae UCG-001 and increased the relative abundance of Bacteroides , Muribaculum , and Lachnospiraceae UCG-001 . Rifaximin treatment attenuated serum interleukin-1β, interleukin-6 and tumor necrosis factor-α, claudin-5 and occludin, which indicated the reduction of systemic inflammation and the protection of the blood-brain barrier integrity. The rifaximin-treated MitoPark mice exhibited better motor and memory performance than did the control mice, with lower microglial activation and increased neuronal survival in the hippocampus. In the patients with PD, 7-day rifaximin treatment caused an increase in the relative abundance of Flavonifractor 6 months after treatment, and the change in plasma proinflammatory cytokine levels was negatively associated with the baseline plasma interleukin-1α level. In conclusion, the present study demonstrated that rifaximin exerted a neuroprotective effect on the transgenic PD mice by modulating gut microbiota. We observed that patients with higher baseline inflammation possibly benefited from rifaximin treatment. With consideration for the tolerability and safety of rifaximin, randomized controlled trials should investigate the disease-modification effect of long-term treatment on select patients with PD.
References: PLoS One. 2013;8(4):e60042. (PMID: 23565181)
Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209. (PMID: 25830558)
J Dent Res. 2003 May;82(5):338-44. (PMID: 12709498)
Hepatology. 2021 Sep;74(3):1660-1673. (PMID: 33421158)
Nature. 2008 May 29;453(7195):620-5. (PMID: 18509436)
Mucosal Immunol. 2021 Jan;14(1):113-124. (PMID: 32433514)
Neurology. 2006 Aug 8;67(3):494-6. (PMID: 16894114)
Mov Disord. 2015 Mar;30(3):350-8. (PMID: 25476529)
BMC Biol. 2020 Jun 9;18(1):62. (PMID: 32517799)
Am J Trop Med Hyg. 2018 Apr;98(4):1152-1158. (PMID: 29436337)
Exp Biol Med (Maywood). 2018 Jan;243(2):159-165. (PMID: 29169241)
Mov Disord. 2012 May;27(6):709-15. (PMID: 21766334)
Lancet Neurol. 2006 Jun;5(6):525-35. (PMID: 16713924)
Lancet Neurol. 2020 Feb;19(2):179-194. (PMID: 31753762)
Curr Opin Gastroenterol. 2021 Nov 1;37(6):572-577. (PMID: 34519701)
Sci Rep. 2019 Jan 17;9(1):167. (PMID: 30655568)
J Vis Exp. 2018 Jun 5;(136):. (PMID: 29939190)
Drugs. 1995 Mar;49(3):467-84. (PMID: 7774516)
Mov Disord. 2012 May;27(6):716-9. (PMID: 22550057)
J Parkinsons Dis. 2019;9(s2):S331-S344. (PMID: 31609699)
Immunology. 2017 Aug;151(4):363-374. (PMID: 28542929)
Cell Host Microbe. 2019 May 8;25(5):668-680.e7. (PMID: 31071294)
Parkinsons Dis. 2011 Feb 22;2011:436813. (PMID: 21403862)
Brain Behav Immun. 2020 Feb;84:218-228. (PMID: 31821847)
Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044)
Cells. 2021 Mar 09;10(3):. (PMID: 33803292)
Neuron. 2019 Aug 21;103(4):627-641.e7. (PMID: 31255487)
Bull Exp Biol Med. 2017 Apr;162(6):734-737. (PMID: 28429209)
Brain Behav Immun. 2009 Jan;23(1):55-63. (PMID: 18678243)
OMICS. 2020 Oct;24(10):592-601. (PMID: 32907488)
Dis Markers. 2015;2015:860120. (PMID: 26586924)
PLoS One. 2015 Aug 26;10(8):e0136722. (PMID: 26308525)
Front Cell Infect Microbiol. 2020 Nov 24;10:572912. (PMID: 33330122)
NPJ Parkinsons Dis. 2021 Mar 10;7(1):27. (PMID: 33692356)
Mov Disord. 2013 Sep 15;28(11):1520-33. (PMID: 24132840)
J Parkinsons Dis. 2020;10(1):193-206. (PMID: 31868677)
Front Immunol. 2021 Apr 22;12:673708. (PMID: 33968085)
Oncogene. 2020 Jun;39(26):4925-4943. (PMID: 32514151)
Brain Sci. 2020 Nov 09;10(11):. (PMID: 33182224)
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S185-8. (PMID: 20082987)
Front Microbiol. 2021 Sep 28;12:728479. (PMID: 34650532)
BMJ. 2018 Jun 13;361:k2179. (PMID: 29899036)
Cell. 2011 May 27;145(5):745-57. (PMID: 21565393)
Inflamm Bowel Dis. 2019 Jan 1;25(1):111-123. (PMID: 29788069)
Cell. 2016 Dec 1;167(6):1469-1480.e12. (PMID: 27912057)
Front Cell Infect Microbiol. 2022 Jan 18;11:761192. (PMID: 35118004)
Curr Biol. 2019 Dec 16;29(24):4218-4230.e8. (PMID: 31786064)
Nat Rev Microbiol. 2021 Jan;19(1):55-71. (PMID: 32887946)
Drugs Aging. 2009;26(9):769-79. (PMID: 19728750)
N Engl J Med. 2010 Mar 25;362(12):1071-81. (PMID: 20335583)
Mov Disord. 2013 Aug;28(9):1241-9. (PMID: 23712625)
Alzheimers Dement (N Y). 2022 Feb 01;8(1):e12225. (PMID: 35128026)
J Neuroinflammation. 2019 Jun 27;16(1):129. (PMID: 31248424)
EBioMedicine. 2019 Jun;44:691-707. (PMID: 31221587)
J Travel Med. 2017 Apr 01;24(suppl_1):S17-S22. (PMID: 28520998)
Front Immunol. 2019 Mar 11;10:277. (PMID: 30915065)
Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. (PMID: 19881343)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Nat Rev Neurol. 2015 Nov;11(11):625-36. (PMID: 26503923)
Mov Disord. 2020 Jul;35(7):1208-1217. (PMID: 32357258)
Dig Dis. 2016;34(3):269-78. (PMID: 27027301)
Nat Commun. 2017 Apr 04;8:15062. (PMID: 28375200)
Microorganisms. 2018 Oct 18;6(4):. (PMID: 30340384)
Acta Neuropathol. 2014 Feb;127(2):235-41. (PMID: 24240814)
J Med Microbiol. 2006 May;55(Pt 5):617-624. (PMID: 16585651)
Brain Res. 2017 Jul 15;1667:41-45. (PMID: 28506555)
JAMA Neurol. 2016 Nov 01;73(11):1316-1324. (PMID: 27668667)
فهرسة مساهمة: Keywords: Parkinson’s disease; gut microbiota; inflammation; rifaximin
المشرفين على المادة: L36O5T016N (Rifaximin)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20221111 Date Completed: 20221114 Latest Revision: 20221210
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9656351
DOI: 10.3390/cells11213468
PMID: 36359864
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells11213468